BOSTON, November 2, 2023 — A 23-year-old man on hemodialysis experienced a surprising complication when treated for high-output heart failure: his condition worsened after starting a relatively new class of heart medications, raising questions about whether the drugs were helping or hindering his recovery.
A Delicate Balance: New Drugs and Existing Conditions
Table of Contents
The case highlights the complexities of treating heart failure in patients with pre-existing kidney disease.
- Angiotensin receptor-neprilysin inhibitors (ARNis) are increasingly used for heart failure, but their effect on hemodialysis patients is unclear.
- This case study details a young man whose high-output heart failure seemed to worsen after starting an ARNI.
- The patient’s case suggests potential cumulative effects of ARNIs and hemodialysis on cardiac function.
- Further research is needed to determine the optimal use of ARNIs in patients undergoing dialysis.
Heart failure, a condition where the heart can’t pump enough blood to meet the body’s needs, is often treated with medications like angiotensin receptor-neprilysin inhibitors (ARNis). But what happens when a patient *also* has kidney failure requiring hemodialysis? That’s the puzzle doctors faced with a young man in Boston, and their findings, published recently, suggest a need for caution.
The Case: A Young Man’s Struggle
The patient, a 23-year-old with a history of chronic kidney disease, was undergoing hemodialysis three times a week when he began experiencing symptoms of high-output heart failure – a rare form where the heart pumps *too much* blood, paradoxically leading to weakness and shortness of breath. Initial tests revealed a significantly elevated cardiac output, and an echocardiogram showed an enlarged heart. Doctors started him on an ARNI, sacubitril/valsartan, hoping to reduce the strain on his heart.
Unfortunately, within weeks of starting the ARNI, the patient’s condition deteriorated. His cardiac output increased further, and his symptoms worsened. Doctors were puzzled. Was the medication simply not working, or was it somehow exacerbating the problem?
Synergistic or Cumulative Effect?
The medical team hypothesized that the ARNI, combined with the physiological effects of hemodialysis itself, might be creating a cumulative effect on the patient’s cardiovascular system. Hemodialysis can lead to fluid shifts and increased cardiac workload, and the ARNI, while intended to help, could be amplifying these effects. “The possibility of a synergistic or cumulative effect between ARNI therapy and hemodialysis-induced cardiac stress warrants consideration,” the doctors noted.
They ultimately decided to discontinue the ARNI and adjust the patient’s hemodialysis regimen. Over time, his cardiac output decreased, and his symptoms gradually improved. This suggests that, in this particular case, the ARNI was contributing to the problem rather than solving it.
Implications for Future Treatment
This case doesn’t mean ARNIs should be avoided in all hemodialysis patients with heart failure. However, it underscores the need for careful monitoring and individualized treatment plans. Doctors need to be aware of the potential for these drugs to interact with the unique physiological challenges faced by patients on dialysis.
Q: Can ARNIs worsen heart failure in patients on hemodialysis?
A: This case suggests that, in some individuals, ARNIs may contribute to increased cardiac output and worsening symptoms of high-output heart failure, particularly when combined with the effects of hemodialysis. More research is needed to understand this interaction.
Further research is crucial to determine the optimal use of ARNIs in this vulnerable population. Until then, a cautious and individualized approach is essential.
Please share your thoughts in the comments below.
